[Clinical trial of suloctidil (sulocton) for the treatment of migraine (preliminary report)].
Suloctidil, a new vasoactive drug, shows certain properties which make it particularly suitable for using in migraine. The author administered Suloctidil in daily doses of 600 mg to 12 patients with migraine during 6 weeks. In 9 cases good results were obtained. Although further investigations are necessary, it seems already now that Suloctidil will enrich the armamentarium of antimigrainous drugs.
D000328:Adult; D002986:Clinical Trials as Topic; D003027:Cluster Headache / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D011412:Propanolamines / Q000627:therapeutic use*; D013468:Suloctidil / Q000627:therapeutic use* / Q000633:toxicity; D014653:Vascular Headaches / Q000188:drug therapy*
D011412:Propanolamines; D013468:Suloctidil
Próba zastosowania preparatu suloctidil (sulocton) w leczeniu migreny (doniesienie wstepne).